US 12,403,129 B2
Isotope-enriched 3-amino-1-propanesulfonic acid derivatives for the treatment of cerebrovascular disease
Jiasheng Lu, Shanghai (CN); Jiamin Gu, Suzhou (CN); and Xianqi Kong, Dollard-des-Ormeaux (CA)
Assigned to RISEN (SUZHOU) PHARMA TECH CO., LTD., Suzhou (CN)
Filed by RISEN (SUZHOU) PHARMA TECH CO., LTD., Jiangsu (CN)
Filed on Nov. 10, 2021, as Appl. No. 17/523,160.
Prior Publication US 2022/0202778 A1, Jun. 30, 2022
Int. Cl. C07C 303/02 (2006.01); A61K 31/131 (2006.01); A61K 31/16 (2006.01); A61K 31/165 (2006.01); A61K 31/417 (2006.01); A61P 9/10 (2006.01); C07C 303/22 (2006.01); C07C 309/14 (2006.01); C07C 309/15 (2006.01)
CPC A61K 31/417 (2013.01) [A61K 31/131 (2013.01); A61K 31/16 (2013.01); A61K 31/165 (2013.01); A61P 9/10 (2018.01)] 2 Claims
 
1. A method for treating cognitive impairment, for delaying or slowing the progression of said cognitive impairment, or for reducing the rate of decline of cognitive function, in a subject having or at risk of having said cognitive impairment or decline of cognitive function, the method comprising administering to said subject a therapeutically effective amount of an isotope-enriched compound, wherein the cognitive impairment or decline of cognitive function is caused by cerebrovascular disease, vascular dementia, stroke, global cerebral ischemia, or hypoxia and is not amyloid-β related, wherein the isotope-enriched compound has the general Formula (I) or a pharmaceutically acceptable salt or ester thereof:
R1R2X—CR2—CH2—CH2—SO3H  (I)
where:
R1 and R2 are independently a hydrogen of natural abundance or a protecting group which have natural abundance or isotope enriched carbon and/or oxygen, said protecting group being selected from acyl, thiocarbonyl, and carbamoyl groups;
R is a hydrogen of natural abundance, or a deuterium (D), or a combination thereof; and
X is a nitrogen of natural abundance or 15N, or a combination thereof;
provided that at least one of X, R, R1 and R2 comprises an atom that is not of natural abundance.